Newsroom.

YONGIN, SOUTH KOREA– The IgNS Executive Committee accepted GC Biopharma's poster, "A New Manufacturing Process to Remove Thrombogenic Factors (II, VII, IX, X, and XI) from a Novel 10% Intravenous Immunoglobulin Gamma Preparation, for presentation at the IgNS 2022 National Conference. GC Biopharma USA Medical Director, Dr. Alan Huber, will be presenting the poster at the conference being held at the Gaylord National Resort and Convention Center in Washington DC from 9/29/22 to 10/2/22.

About GC Biopharma

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers lifesaving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein and vaccine product manufacturers in the world and has been dedicated to quality healthcare solutions for more than half a century. Green Cross Corporation updated its corporate brand to GC Biopharma in early 2018. Green Cross Corporation remains the company's legal name.

This press release may contain forward-looking statements that express GC Biopharma's and GC Biopharma USA, Inc.'s management's current beliefs and expectations. Such views do not represent any guarantee by either entity or its government of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma and GC Biopharma USA, Inc. undertake no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements they may make, except as required by law or stock exchange rule.